23andMe Holding Co. Stock News

Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a clinical trial of 23ME-00610 to be presented Data from neuroendocrine and ovarian cancer patient cohorts in the Phase 1/2a

Matterport is being acquired by CoStar in a $1.7 billion cash and stock deal. The company not only has an excellent proprietary technology, but also a strong balance sheet.

Like a number of companies that went public during the pandemic, 23andMe has for months been trying to manage a terrible case of SPAC-itis, an inflammation that causes plunging stock values due to the

23andMe Holding Co.'s shares surged after CEO Anne Wojcicki revealed plans to potentially take the struggling DNA testing firm private. The announcement follows the company's dismal performance since

23andMe (ME) chief executive Anne Wojcicki is seeking to take the DNA-testing company private less than three years after it went public, the firm said in a Securities and Exchange Commission (SEC) fi

23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private

Battered 23andMe Holding Co. (NASDAQ: ME), its shares driven down to penny stock levels, may disappear from the public markets completely.

23andMe co-founder and chief executive Anne Wojcicki is considering making an offer to buy the genetics testing company in a potential go-private transaction, a regulatory filing on late Wednesday sho

SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, will present data on its two clinical stage prog

Shares of 23andMe have been hurt severely since the company's stock market debut in 2021. Several billionaire investors acquired shares of 23andMe during the last three months of 2023.

The at-home genetic testing company is dealing with financial woes and a security breach. What does that mean for customers?

23andMe reported dismal third-quarter fiscal 2024 results and discussed splitting itself in two to help juice its stock price.

Shares of 23andMe Holding Co. fell 15.8% Thursday after the DNA-testing company fiscal third-quarter sales declined 33%, weighed down by lower consumer services and research revenue.

23andMe Holding Co. (ME) Q3 2024 Earnings Call Transcript

23andMe stock is down over 95% from its peak, cutting its value from $6 billion to $345 million. The genetic-testing company is facing financial and strategic challenges, and was hacked last year.